Semaglutide 10mg (Ozempic)

GLP-1, short for glucagon-like peptide-1, is a short, naturally occurring peptide hormone of just 30 to 31 amino acids. Its primary physiologic function is to lower blood sugar levels by naturally enhancing insulin secretion. It also helps protect beta cell insulin stores by promoting insulin gene transcription, and it has been linked with neurotrophic effects in the brain and central nervous system. In the GI system it significantly decreases appetite, by delaying gastric emptying and reducing intestinal motility. Preliminary research reports effects in the heart, fat, muscles, bones, liver, lungs and kidneys as well.

Most GLP-1 research has concerned the treatment and prevention of diabetes along with appetite suppression. A second strand looks at the potential cardiovascular benefits of the peptide. Newer work, and therefore less robust work, asks whether GLP-1 can stave off neurodegenerative disease. That strand is the youngest and also the fastest growing, following the finding that the peptide slows or prevents the accumulation of amyloid beta plaques in Alzheimer's disease.

Semaglutide is a 31 amino acid analogue of human glucagon-like peptide-1, an incretin hormone released from intestinal L cells after a meal. Native GLP-1 is destroyed within about two minutes by dipeptidyl peptidase-4, which cleaves it at the alanine in position 8. Semaglutide substitutes that residue with alpha-aminoisobutyric acid, a non-proteinogenic amino acid the enzyme cannot cut, and that single change is the foundation of the molecule.

Resisting DPP-4 alone would still leave rapid renal clearance. The second design element addresses that: a C18 fatty diacid is attached through a gamma-glutamate and two short polyethylene glycol spacers at position 26. The fatty acid binds albumin reversibly with high affinity, so most of the circulating drug travels bound to a protein too large to filter at the glomerulus, and it is released slowly as free drug is consumed. The result is a half-life of about a week rather than minutes.

At the receptor, semaglutide is a full agonist at the GLP-1 receptor, a class B G protein-coupled receptor. Signalling is predominantly through Gs and cyclic AMP. In pancreatic beta cells that potentiates glucose-stimulated insulin secretion, which is why the effect is glucose-dependent and does not drive insulin release when glucose is low. In the hypothalamus and hindbrain, receptor activation reduces appetite and food intake, and in the stomach it slows gastric emptying.

The most important thing GLP-1 does is probably what is referred to as the "incretin effect". Incretins are a group of metabolic hormones, released by the GI tract, which cause a decrease in blood glucose levels. In rodent models, GLP-1 is one of the two hormones that matter most in stimulating that effect; the other is GIP.

GIP circulates at levels roughly 10 times higher than GLP-1, yet the evidence makes GLP-1 the more potent of the two molecules, particularly where blood glucose is quite high. A GLP-1 receptor has been identified on the surface of pancreatic beta cells, which establishes that GLP-1 directly stimulates the exocytosis of insulin from the pancreas. Combined with sulfonylurea drugs, GLP-1 boosts insulin secretion enough to cause mild hypoglycemia in up to 40% of subjects[1].

Research in animal models suggests that GLP-1 stimulates the growth and proliferation of pancreatic beta cells, and that it may drive the differentiation of new beta cells from progenitors in the pancreatic duct epithelium. It has also been shown to inhibit beta cell apoptosis[1]. Taken in sum, those effects tip the usual balance of beta cell growth and death toward growth, which is what suggests the peptide may be useful in treating diabetes and in protecting the pancreas against insult that harms beta cells.

In one particularly compelling trial, GLP-1 inhibited the beta cell death caused by enhanced levels of inflammatory cytokines. Mouse models of type 1 diabetes go further still: GLP-1 protects islet cells from destruction there, and may in fact be a useful means of preventing the onset of type 1 diabetes[2].

Research in mouse models suggests that delivering GLP-1 into the brain reduces the drive to eat and inhibits food intake[3]. The peptide appears to enhance feelings of satiety, so that the animal feels fuller and hunger falls indirectly.

Clinical studies have shown that twice daily administration of GLP-1 receptor agonists causes gradual, linear weight loss. Sustained over a long period, that weight loss is associated with significant improvement in cardiovascular risk factors and a reduction in hemoglobin A1c, the latter of these being a proxy marker for the severity of diabetes and the quality of blood sugar control attained via treatment[4].

GLP-1 receptors are distributed throughout the heart, where in certain settings they improve cardiac function by boosting heart rate and reducing left ventricular end-diastolic pressure[5]. More recent evidence has suggested the peptide could also play a role in decreasing the overall damage caused by a heart attack.

It appears to improve glucose uptake by cardiac muscle, which gives struggling ischemic heart muscle cells the nutrition they need to keep functioning and to avoid programmed cell death. That increase in glucose uptake appears to be independent of insulin[6]. Large infusions of GLP-1 into dogs improved left ventricular performance and reduced systemic vascular resistance[7].

There is some evidence to suggest that GLP-1 can improve learning and help protect neurons against neurodegenerative diseases such as Alzheimer's disease. In one study it enhanced associative and spatial learning in mice, and improved learning deficits in mice carrying specific gene defects[8].

Further rodent research shows GLP-1 protecting against excitotoxic neuron damage, giving complete protection to rat models of neurodegeneration against glutamate-induced apoptosis. The peptide can even stimulate neurite outgrowth in cultured cells[9].

In mouse models, GLP-1 and its analogue exendin-4 both reduce levels of amyloid-beta in the brain along with the beta-amyloid precursor protein found in neurons. Amyloid beta is the primary component of the plaques observed in Alzheimer's disease[10].

Native GLP-1 would be a useless drug. It is cleared in about two minutes, cut by dipeptidyl peptidase-4 at the alanine in position 8 and then filtered rapidly by the kidney. Any therapeutic GLP-1 analogue is fundamentally an answer to those two problems, and semaglutide answers them separately.

The first answer is chemical. Alpha-aminoisobutyric acid at position 8 is not a natural amino acid and DPP-4 does not recognise it as a substrate. Enzymatic destruction stops being the rate-limiting step.

The second answer is physical rather than chemical. The C18 diacid at position 26 does not change how the peptide signals; it changes where the peptide is. Bound to albumin, the molecule is too large to be filtered at the glomerulus, and the binding is reversible, so the albumin pool behaves as a slow-release reservoir. Together the two changes take the half-life from minutes to about a week.

The insulin secretion that GLP-1 receptor agonism produces is potentiation rather than initiation. The receptor raises cyclic AMP in the beta cell, which amplifies the secretory response to glucose, but it does not by itself trigger release when glucose is low.

That is a property of the mechanism rather than of the dose, and it is why the pharmacology of this class differs fundamentally from agents that drive insulin release regardless of glucose. It also explains why the appetite and gastric emptying effects, which are receptor-mediated at other sites, do not share the same self-limiting property.

SUSTAIN-6 reported cardiovascular benefit in people with type 2 diabetes, which left open whether the effect followed from better glycaemic control or from something else. SELECT was designed to answer that: it enrolled people with overweight or obesity and established cardiovascular disease but without diabetes, and still reported a reduction in the cardiovascular composite endpoint.

That design difference is what makes the two trials complementary rather than repetitive. Neither establishes a mechanism for the cardiovascular effect, which remains debated and is not fully explained by weight change or by glucose lowering alone.

Both are outcome trials in defined populations under protocol. Nothing in either is a statement about what happens outside those populations.

Semaglutide is supplied for laboratory work as a lyophilised powder and is markedly more stable dry than in solution. The acylation makes it more hydrophobic than native GLP-1, which affects its chromatographic retention and is worth accounting for when interpreting an HPLC trace against a reference.

Because the molecule carries a fatty acid chain, related-substance profiles can include des-acyl and mis-acylated species that a purity figure alone will not distinguish from the intended product. The analytical method stated on a certificate therefore matters as much as the percentage it reports.